Quantcast
Close Window
   
Welcome :o)
Welcome to another year exposing the harms of Johnson & Johnson products and the executives that care more about money than human health...
 
There really is a highly effective way to put an end to mass tort lawsuits: GET JOHNSON & JOHNSON AND SUBSIDIARY KNOWN DEFECTIVE, HARMFUL AND/OR TOXIC PRODUCTS OFF THE GLOBAL MARKET
 
This work is 100% independent. I am NOT a victim, NOT a lawyer, NOT paid by anyone other than visitors to the site. And no, I do not own any stock in Johnson & Johnson.
 
Emily.
HomeAbout

Content List
100+ articles of harm and corruption by Johnson & Johnson and subsidiary products.
Click for content list...

Glad to see you :o)
March 2017 marks FIVE YEARS of work exposing harm, corruption and massive costs of flood of KNOWN HARMFUL Johnson & Johnson products.
 
This web site currently has the attention of:
click link to validate IP address through whatismyipaddress.com
 
US GOVERNMENT:
US Senate
US Department of Defense
US Department of Justice
US Homeland Security
 
GLOBAL FINANCIAL INSTITUTIONS:
...including many Johnson & Johnson shareholders ;o)
 
Vanguard
The Bank of New York Mellon Corp
Lloyds Banking Group PLC
Royal Bank of Canada
Bank of America
Harris Trust & Savings Bank
Deutsche Bank
Macquarie Bank
PNC Bank
Crédit Agricole Bank
Royal Bank of Scotland
Raymond James Financial
BlackRock Financial Management
...and many, many more from all over the world ;o)
 
I am not paid by lawyers, doctors, etc - ONLY by visitors to the web site, the PEOPLE I am working for, PEOPLE like you. Currently reduced to only a part-time job, I donate the remainder of my time to take care of all the work involved in maintaining the site by doing the research, search engine optimized content, responding to victim emails and social media to create awareness among consumers to prevent new injuries as well as continue increasing awareness among Johnson & Johnson shareholders and global health organizations. Feel free to browse list of notable visitors to the web site.
 
God Bless You and Yours and keep you safe from harm,
Emily
 
Please send financial support to keep this very important GLOBAL consumer safety effort going...
 
Enter any amount in GiftBox below or PayPal to Email:
 
emily@johnsonandtoxin.com
 
$.00   
 
Sponsored in part by...
Examining Medicine An in-depth comprehensive, frequently updated look at extreme risks and permanent brain damage caused by psychiatric drugs.
----- / / -----
Fiddaman Blog Bob Fiddaman has been writing about the dangers of antidepressants since 2006. In 2011 he was presented with two human rights awards from the Citizens Commission on Human Rights.
----- / / -----
Special Needs Advocate Power Join me as we work hard to ensure what our very special children need.

Letter to J P Morgan Michael Weinstein RE: $JNJ 3rd quarter 2013 Conference Call
Since Orsinger and Caruso danced around issues of price competition and lack of consumer sales growth and basically said nothing, I figured I'd give him a real answer.

Keywords: obama, Michael Weinstein, jp morgan, JNJ, invest, stock, financial, analyst
Date Created/Edited: October 17, 2013
 
Michael Weinstein
J. P. Morgan and Company
Healthcare Equipment and Supplies
277 Park Avenue Floor 39
New York, New York 10172
United States
 
RE: Johnson & Johnson 3rd Quarter Teleconference: 14 October 2013
 
Dear Michael Weinstein,
 
My name is Emily Patterson. I am the creator of and researcher for a web site called Johnson and Toxin. After reading the transcript of the 3rd quarter 2013 teleconference with Johnson & Johnson Vice President of Finance, Dominic Caruso and Johnson & Johnson Worldwide Chairman of DePuy Synthes companies, Michel Orsinger, I felt your questions required a little more realistic clarification.
 
I feel the interesting questions you asked during the teleconference deserved a far deeper, and more accurate, explanation. You were wondering if Dominic Caruso was referring to lower price competition in the U.S., global or a combination.
 
After recalls of over 100,000 defective hips, TVTMesh, defective knees, anal staplers, and more over the last few years, Johnson & Johnson is paving the way for competitors to surpass the pathetically low quality and testing standards at Johnson & Johnson and subsidiary companies. Johnson & Johnson prices must stay inflated to compensate for billions of dollars in lawsuits and settlements from these known defective devices. This opens the door for companies with higher ethics, standards and quality controls to charge far less for similar products - because they are far superior to the products offered by Johnson & Johnson.
 
In your statement you mentioned that there was only 1% growth in the Johnson & Johnson Consumer Segment. As you know, the previous CEO, Bill Weldon, allowed Johnson & Johnson facilities to deteriorate to the point of literal urine bottles in closets. Although it was promised that the facilities would be back up and running at the end of last year, excuse after excuse and $100 million later, Johnson & Johnson is still under consent decree with the United States Food and Drug Administration.
 
In addition, Johnson & Johnson is still experiencing recalls of products in many countries: January, Aveeno Baby Lotion in the U.S.; March, KY Lubricants in the U.S.; May, baby powder in India (with FDA of India shutting down plant); May, Children's Tylenol in South Korea with ensuing product restrictions; June, Yogurt drink in the United Kingdom; September, Children's Motrin in the U.S. So, as you can see, recalls continue to be an issue, reducing sales and potential for growth until Johnson & Johnson finds a way to improve the consistent quality of their products.
 
One other point you should consider, as consumers become educated as to the risks of cancer associated with certain ingredients in Johnson & Johnson products, especially baby products, many are choosing other safer sources with fewer chemicals to reduce health risks for their children. This is yet another factor reducing consumer sales growth.
 
I hope this provided a more detailed explanation for your concerns,
 
Emily Patterson cc:
Alex Gorsky
Dominic Caruso
Michel Orsinger
Barack Obama

Special Sections....
 
Mesh Files
Baby Powder (talc) Files
Risperdal Files
Levaquin Files
Xarelto Files
Hips Files
Letters to Shareholders
SEC Lawsuits Files

 
Recent Content....
The Fastest Growing Segment of Johnson & Johnson Is... (2016, November 15)
Growing over 29% in 2016, this is definitely the fastest growing segment of Johnson & Johnson!
johnson & johnson, J&J, JNJ, 2016, lawsuit, lawsuits, tort, liability
 
Third Quarter 2016 Lawsuits Against Johnson & Johnson Still Exploding! Now 99,000! (2016, November 15)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 99,000.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
The Difference Between Guinea Pig and Cash Cow (2016, September 27)
People keep saying pharma is using us as 'guinea pigs'. Uh, not quite. Take a minute to learn the difference between a 'guinea pig' and a 'cash cow'.
guinea pig, immunization, vaccination, profit, harm, autism, disability, asthma
 
Johnson & Johnson Victims at Risk of RE-Victimization (2016, August 22)
If you are currently a victim of a known harmful Johnson & Johnson subsidiary product and have high medical needs due to your injuries, you are at increased risk of becoming a victim of another known harmful Johnson & Johnson subsidiary product.
jnj, johnson and johnson, johnson & johnson, victim, mesh, hip, levaquin, risperdal
 
Wealthy Most at Risk for Harm by Johnson & Johnson and Subsidiary Products (2016, August 22)
If you make over $100,000 a year, you are far more likely than lower incomes to become a victim of a Johnson & Johnson and/or subsidiary product.
healthcare, cost, co-pay, risk, deductable, insurance, victim, salary
 
Second Quarter 2016 Lawsuits Against Johnson & Johnson Leap Again From 82,200 to 90,700 (2016, August 4)
Growing every quarter, lawsuits against Johnson & Johnson in United States alone are now well over 90,700.
talc, risperdal, asr, hip, baby powder, tvt, mesh, lawsuit
 
Johnson & Johnson Animas Defective Diabetes Devices (2016, August 4)
Gosh and golly gee willikers, yet another Johnson & Johnson subsidiary, Animas, totally sucks, jah?
Johnson and Johnson, Johnson & Johnson, animas, vibe, diabetes, insulin, device, pump
 
Johnson & Johnson Ethicrap, I Mean EthiCON, More JNJ JUNK (2016, July 25)
As I've mentioned, Johnson & Johnson has so many bad products I have to put a bunch in each article now to try to keep up. Now for EthiCON crap.
Johnson and Johnson, Johnson & Johnson, ethicon, harmonic ace, morcellator, physiomesh, secure strap, stapler
 
Johnson and Johnson Janssen Xarelto Slaughter (2016, July 8)
Overstating benefits, downplaying (or not disclosing) risks. Xarelto by Johnson and Johnson Janssen killing people left and right. Over 500 DEAD, 7,100 lawsuits already. Lovely, eh?
false, marketing, death, dead, xarelto, FDA, lawsuit, Janssen
 
This Convinced THREE Juries That Johnson and Johnson Talc Increases Ovarian Cancer (2016, May 14)
One very simple fact convinced THREE juries that Johnson & Johnson talc increases risk of developing ovarian cancer.
Johnson and Johnson, Johnson & Johnson, baby, powder, cancer, lawsuit, ovarian, talc
 

 


 
Resources:
1. TRANSCRIPT (2013, October 15). Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript. Seeking Alpha. Retrieved from http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?page=11&p=qanda&l=last
 
 
All contents Copyright © 2012-2016 Emily Patterson / Johnson and Toxin. All rights reserved.
 
Web Site and Admin Info:
Home
About
Contact
Disclaimers
Privacy Policy
Site Statistics
Site Resources
Financial Disclosure

 
Recently Posted:
2015 Johnson & Johnson US Lawsuit Update: Jump from 48,500 to 56.500
 
Johnson & Johnson Plans to Expand Healthcare Cost Crisis and Product Liability in Asia
 
Who REALLY Pays for Drug Development? US TAXPAYERS - $21 BILLION for fiscal year 2014
 
Johnson & Johnson Janssen Xarelto Marketed In Violation of FDA Regulations
 
Johnson & Johnson Destroys Thousands of Files Related to Vaginal Mesh
 
Johnson & Johnson: The Global Lawsuit Company


 
 
Most Popular:
The Ever-Growing Number of Lawsuits Against Johnson & Johnson
 
Johnson & Johnson Credo Analysis
 
Johnson & Johnson $4 Billion for DePuy Hip Harm in U.S., With Lawsuits in at Least 4 More Countries